Tegaserod: A new 5-HT4 agonist

Journal of Clinical Gastroenterology

Volumn 34, Issue 1, 2002, Pages 27-33

  Lacy, B E ^a   Yu, S ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Constipation; Irritable bowel syndrome; Serotonin; Tegaserod; Zelnorm

Indexed keywords

SEROTONIN 4 AGONIST; TEGASEROD;

ABDOMINAL PAIN; CONSTIPATION; HUMAN; INTESTINE INNERVATION; INTESTINE MOTILITY; IRRITABLE COLON; PRIORITY JOURNAL; REVIEW; SEROTONIN METABOLISM;

ABDOMINAL PAIN; ANIMALS; COLONIC DISEASES, FUNCTIONAL; CONSTIPATION; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; INDOLES; SEROTONIN; SEROTONIN AGONISTS;

EID: 0036138537     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200201000-00006     Document Type: Review

References (47)

1. Serotonin: Synthesis and release from the myenteric plexus of the mouse intestine
2. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel
3. Serotonin: The neurotransmitter for the 90's
4. Serotonin: A mediator of the brain-gut connection
5. The serotonin 5-HT4 receptor: 1. Design of a new class of agonists and receptor map of the agonist recognition site
6. The serotonin 5-HT4 receptor: 2. Structure-activity studies of the indole carbazimidamide class of agonists
7. The properties of a new prokinetically active drug, SDZ HTF 919
8. 5-Hydroxytryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine
9. Substituted carbazimidamides, a new class potent and selective 5-HT4 receptor agonists and antagonists
10. Stimulation of colonic propulsion by 5-HT4 receptor agonists: Synergism by δ opioid receptor antagonists
11. Preclinical and clinical effects of SDZ HTF 919, a new prokinetic drug, on colonic transit
12. SDZ HTF 919 stimulates canine colonic motility and transit in vivo
13. Effects of tegasrod (HTF 919) on gastrointestinal motility and transit in awake rats
14. Tegaserod (HTF 919), a new 5-HT4 receptor partial agonist, increases post-operative gastric and small intestinal motility in rats
15. Investigations on a 5-HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: Effects on gastrointestinal motility and impaired gastric emptying
16. Modulation of rectal spinal afferent sensitivity via 5-HT4 receptors
17. Dose-dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist
18. Antinociceptive properties of HTF 919 (Tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats
19. Simultaneous. P.O. and I.V. pharmacokinetic modelling of the novel selective 5-HT4 receptor agonist SDZ HTF 919 in humans
20. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration
21. Effect of meal timing not critical for the pharmacokinetics of Tegaserod (HTF 919)
22. Pharmacokinetics and safety of SDZ HTF 919, a new promotile drug, in healthy subjects and patients with hepatic cirrhosis
23. Pharmacekinetics of SDZ HTF 919 not altered in subjects with severe renal insufficiency requiring heamodialysis
24. Titration regimen indicates partial 5-HT agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome
25. Similar pharmacokinetics of tegaserod (HTF 919) in patients with constipation and dirrhea-predominant irritable bowel syndrome
26. Tegaserod (HTF 919) pharmacokinetics similar in patients with irritable bowel syndrome and gastroesophageal reflux disease
27. Effects of age and gender on the pharmacokinetics of the novel 5-HT4 receptor partial agonist tegaserod
28. Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
29. Tegaserod (HTF 919) does not affect theophylline pharmacokinetics (PK) in healthy subjects
30. Tegaserod (HTF 919) does not decrease the effectiveness of an oral contraceptive when co-administered to healthy female subjects
31. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride, and erythromycine on cardiac repolarization in the isolated rabbit heart
32. Tegaserod has a favorable safety & tolerability profile in patients with constipation predominamt and alternating forms of irritable bowel syndrome
33. Tegaserod is well tolerated over the short and long-term in patients with irritable bowel syndrome
34. The partial 5-HT4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome
35. Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in clinical trial of irritable bowel syndrome with HTF 919
36. The 5-HT4 partial agonist tegaserod improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome
37. Tegaserod, a partial 5-HT4 agonist, improves abdominal bloating and altered stool consistency in irritable bowel syndrome
38. Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome
39. Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserod
40. Tegaserod (HTF919), a 5-HT4 receptor partial agonist, accelerates gastrointestinal (GI) transit
41. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine 4 receptor agonist
42. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit constipation
43. In vivo modulation of left colonic motor function by a 5-HT4 mechanism in healthy humans
44. Tegaserod accelerates orocecal transit in patients with constipation predominant irritable bowel syndrome
45. The effects of tegaserod (HTF 919) on esophageal acid exposure in gastroesophageal reflux disease (GERD)
46. Tegaserod provides relief of symptoms in female patients with irritable bowel syndrome (IBS) suffering from abdominal pain and discomfort, bloating and constipation